Zur Seitenansicht
 

Titelaufnahme

Titel
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma : a single-center analysis
Verfasser / VerfasserinLamm, Wolfgang ; Rabitsch, W. ; Bojic, M. ; Wohlfarth, P. ; Leiner, M. ; Schörgenhofer, C. ; Kalhs, P. ; Schulenburg, A. ; Sillaber, C. ; Mitterbauer, M. ; Sperr, W.R. ; Jäger, U. ; Skrabs, U. ; Greinix, K.
Erschienen in
Journal of Cancer Research and Clinical Oncology, 2016, Jg. 142, H. 6, S. 1307-1314
ErschienenSpringer, 2016
SpracheEnglisch
DokumenttypAufsatz in einer Zeitschrift
Schlagwörter (EN)Hodgkin lymphoma / Allogeneic HSCT / Alemtuzumab-BEAM
URNurn:nbn:at:at-ubmuw:3-1219 Persistent Identifier (URN)
DOI10.1007/s00432-016-2134-3 
Zugriffsbeschränkung
 Das Werk ist frei verfügbar
Dateien
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma [0.46 mb]
Links
Nachweis
Klassifikation
Zusammenfassung (Englisch)

Purpose

Treatment of refractory Hodgkin disease deserves specific considerations. Recently, alemtuzumab-BEAM has been introduced in allogeneic hematopoietic stem cell transplantation (HSCT) in these patients.

Methods

We retrospectively analyzed the outcome of 20 patients with relapsed/refractory Hodgkins lymphoma (HL) who received allogeneic HSCT following conditioning therapy with alemtuzumab-BEAM.

Results

Treatment-related toxicity was tolerable. Half of the patients (50 %) had infections. Of these, 50 % were found to have pneumonia or catheter-related infections. In 20 %, an oral mucositis was observed. Acute graft-versus-host disease (GvHD) (grade 2) was seen in three patients. Complete remission (CR) could be achieved in 17 patients (85 %), 2 patients had persistent Hodgkin disease, and 1 patient died from infection prior to CR evaluation. Median progression-free survival and overall survival were 17.9 and 67.5 months, respectively. From the 17 CR patients, 8 had a relapse after a median of 10 months. Notably, of the eight patients relapsing after HSCT, all patients received another salvage treatment and four patients are still alive, whereas the other four patients died due to further progress. Six out of the remaining nine patients are still in CR, whereas the other three died from chronic GvHD and multi-organ failure. Overall, seven patients experienced chronic GvHD.

Conclusion

In summary, alemtuzumab-BEAM is a well-tolerated conditioning therapy for allogeneic HSCT with high response rates in refractory HL.

Statistik
Das PDF-Dokument wurde 2 mal heruntergeladen.
Lizenz
CC-BY-Lizenz (4.0)Creative Commons Namensnennung 4.0 International Lizenz